FDA gives pSivida a poke in the eye

FDA gives pSivida a poke in the eye

In its third complete response (rejection) letter (CRL), the FDA told pSivida's licencng partner Alimera that it couldn't green-light Iluvien — a single dose treatment for diabetic macular edema — because the benefits didn't outweigh the risks. The

10
Like
Save

Comments

Write a comment

*